FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979062502> ?p ?o ?g. }

• W2979062502 endingPage "52" @default.
• W2979062502 startingPage "44" @default.
• W2979062502 abstract "Purpose Double-hit lymphomas and triple-hit lymphomas (DHL/THL), also known as high-grade B-cell lymphoma with MYC and BCL2 or BCL6 rearrangements, are associated with chemoresistance and inferior survival. However, whether radiation therapy (RT) efficacy is altered in DHL/THL is less well characterized. Among patients with relapsed or refractory large B-cell lymphoma (R/R LBCL), we compared rates and durability of response between patients with and without DHL/THL. Methods and Materials We retrospectively reviewed consecutive R/R LBCL patients who were irradiated at a single institution from January 2008 to June 2017. Patients in whom c-MYC rearranged status was known were evaluated for response to RT, in-field control, progression-free, and overall survival. Results Among 245 irradiated patients with LBCL, 41 patients with confirmed c-MYC status were treated for R/R disease (14 DHL/THL, 27 non-DHL/THL) and formed our cohort. Compared with non-DHL/THL, more DHL/THL patients had progressive disease at RT (71% vs 48%), had larger gross tumor volumes (GTV; median 696 mL vs 117 mL), and were treated with palliative intent (71% vs 41%). Despite similar RT doses (median 35 Gy), radiographic complete response rate was lower among DHL/THL patients: 14.3% versus 64.7% (P = .01). With a median 2 years of follow-up, one in-field failure was observed in each group. DHL/THL patients had inferior progression-free survival (7% vs 46%; P = .02) and overall survival (14% vs 68%; P = .03) at 6 months. Conclusions R/R LBCL is responsive to RT, although rates of response are lower among DHL/THL patients. Given poor survival after RT, in-field control was hard to evaluate in this cohort. Larger cohorts are required to better elucidate whether differences in response rates are driven by larger disease burden at RT versus tumor biology. These findings are of increasing pertinence in light of use of RT as bridging therapy to cellular immunotherapies." @default.
• W2979062502 created "2019-10-10" @default.
• W2979062502 creator A5004025497 @default.
• W2979062502 creator A5004976884 @default.
• W2979062502 creator A5005281918 @default.
• W2979062502 creator A5012307259 @default.
• W2979062502 creator A5018792372 @default.
• W2979062502 creator A5020858509 @default.
• W2979062502 creator A5033562711 @default.
• W2979062502 creator A5037938194 @default.
• W2979062502 creator A5048827573 @default.
• W2979062502 creator A5051296565 @default.
• W2979062502 creator A5053901128 @default.
• W2979062502 creator A5064080252 @default.
• W2979062502 creator A5071844603 @default.
• W2979062502 creator A5079426839 @default.
• W2979062502 creator A5088459737 @default.
• W2979062502 date "2020-01-01" @default.
• W2979062502 modified "2023-10-01" @default.
• W2979062502 title "Impact of Double- or Triple-Hit Pathology on Rates and Durability of Radiation Therapy Response Among Patients With Relapsed or Refractory Large B-Cell Lymphoma" @default.
• W2979062502 cites W1502170811 @default.
• W2979062502 cites W1514488017 @default.
• W2979062502 cites W1978932947 @default.
• W2979062502 cites W1986579589 @default.
• W2979062502 cites W1995981720 @default.
• W2979062502 cites W1997353354 @default.
• W2979062502 cites W2000739200 @default.
• W2979062502 cites W2023809901 @default.
• W2979062502 cites W2028850684 @default.
• W2979062502 cites W2037796411 @default.
• W2979062502 cites W2043622833 @default.
• W2979062502 cites W2057239580 @default.
• W2979062502 cites W2058024051 @default.
• W2979062502 cites W2077522084 @default.
• W2979062502 cites W2090986407 @default.
• W2979062502 cites W2130842899 @default.
• W2979062502 cites W2132974458 @default.
• W2979062502 cites W2133201432 @default.
• W2979062502 cites W2150587745 @default.
• W2979062502 cites W2153667947 @default.
• W2979062502 cites W2158267770 @default.
• W2979062502 cites W2167248512 @default.
• W2979062502 cites W2310716991 @default.
• W2979062502 cites W2524880168 @default.
• W2979062502 cites W2525478941 @default.
• W2979062502 cites W2610797169 @default.
• W2979062502 cites W2760579949 @default.
• W2979062502 cites W2790373585 @default.
• W2979062502 cites W2800007519 @default.
• W2979062502 cites W2903062212 @default.
• W2979062502 cites W2903225254 @default.
• W2979062502 doi "https://doi.org/10.1016/j.prro.2019.09.013" @default.
• W2979062502 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31585205" @default.
• W2979062502 hasPublicationYear "2020" @default.
• W2979062502 type Work @default.
• W2979062502 sameAs 2979062502 @default.
• W2979062502 citedByCount "6" @default.
• W2979062502 countsByYear W29790625022020 @default.
• W2979062502 countsByYear W29790625022021 @default.
• W2979062502 countsByYear W29790625022022 @default.
• W2979062502 crossrefType "journal-article" @default.
• W2979062502 hasAuthorship W2979062502A5004025497 @default.
• W2979062502 hasAuthorship W2979062502A5004976884 @default.
• W2979062502 hasAuthorship W2979062502A5005281918 @default.
• W2979062502 hasAuthorship W2979062502A5012307259 @default.
• W2979062502 hasAuthorship W2979062502A5018792372 @default.
• W2979062502 hasAuthorship W2979062502A5020858509 @default.
• W2979062502 hasAuthorship W2979062502A5033562711 @default.
• W2979062502 hasAuthorship W2979062502A5037938194 @default.
• W2979062502 hasAuthorship W2979062502A5048827573 @default.
• W2979062502 hasAuthorship W2979062502A5051296565 @default.
• W2979062502 hasAuthorship W2979062502A5053901128 @default.
• W2979062502 hasAuthorship W2979062502A5064080252 @default.
• W2979062502 hasAuthorship W2979062502A5071844603 @default.
• W2979062502 hasAuthorship W2979062502A5079426839 @default.
• W2979062502 hasAuthorship W2979062502A5088459737 @default.
• W2979062502 hasConcept C121332964 @default.
• W2979062502 hasConcept C126322002 @default.
• W2979062502 hasConcept C142424586 @default.
• W2979062502 hasConcept C143998085 @default.
• W2979062502 hasConcept C159654299 @default.
• W2979062502 hasConcept C203014093 @default.
• W2979062502 hasConcept C2777537477 @default.
• W2979062502 hasConcept C2778453870 @default.
• W2979062502 hasConcept C2779338263 @default.
• W2979062502 hasConcept C2989005 @default.
• W2979062502 hasConcept C509974204 @default.
• W2979062502 hasConcept C71924100 @default.
• W2979062502 hasConcept C72563966 @default.
• W2979062502 hasConcept C87355193 @default.
• W2979062502 hasConcept C90924648 @default.
• W2979062502 hasConcept C96926380 @default.
• W2979062502 hasConceptScore W2979062502C121332964 @default.
• W2979062502 hasConceptScore W2979062502C126322002 @default.
• W2979062502 hasConceptScore W2979062502C142424586 @default.
• W2979062502 hasConceptScore W2979062502C143998085 @default.
• W2979062502 hasConceptScore W2979062502C159654299 @default.
• W2979062502 hasConceptScore W2979062502C203014093 @default.

• next